The pharmacodynamics of rocuronium in pediatric patients anesthetized with halothane

G Bikhazi1, F Marin, N J Halliday

  • 1Department of Anesthesiology, University of Miami School of Medicine, P.O. Box 016370, 33101, Miami, FL, USA.

Journal of Anesthesia
|April 10, 2013
PubMed

Insights

Rocuronium, a neuromuscular blocker, was studied in children aged 4-14. It demonstrated a rapid onset and shorter duration of action compared to other steroid muscle relaxants, with specific effective doses determined for intubation and maintenance.

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Pediatric Medicine

Background:

  • Neuromuscular blocking agents are crucial in pediatric anesthesia.
  • Rocuronium (ORG 9426) is a non-depolarizing neuromuscular blocker.
  • Understanding its potency and duration in children is essential for safe anesthetic practice.

Purpose of the Study:

  • To determine the neuromuscular blocking potency of rocuronium in pediatric patients (4-14 years old) undergoing halothane anesthesia.
  • To establish the effective dose for 50% (ED50), 90% (ED90), and 95% (ED95) neuromuscular blockade.
  • To evaluate the duration of action and cumulative effects of rocuronium for intubation and maintenance of neuromuscular blockade.

Main Methods:

  • Ulnar nerve stimulation and thumb muscle contraction recording were used to assess neuromuscular blockade.
  • Rocuronium was administered in incremental doses (0.12-0.24 mg·kg(-1)) to four groups of 12 pediatric patients each.
  • Dose-response relationships were analyzed using log dose-probit regression to determine ED values.

Main Results:

  • The ED50, ED90, and ED95 of rocuronium were determined to be 0.18, 0.34, and 0.40 mg·kg(-1), respectively.
  • A total dose of 0.3 mg·kg(-1) facilitated tracheal intubation in most patients.
  • Rocuronium exhibited a short duration of action with minimal cumulative effects upon repeated administration, and residual block could be reversed with edrophonium.

Conclusions:

  • Rocuronium demonstrates a rapid onset and shorter duration of action in pediatric patients compared to other steroid-type muscle relaxants.
  • Its predictable potency and short duration make it suitable for tracheal intubation and maintenance of neuromuscular blockade in children.
  • Further research may explore its use in different pediatric anesthetic contexts.

Related Concept Videos

Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...